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Mineralocorticoid receptor antagonism limits
experimental choroidal neovascularization and
structural changes associated with neovascular
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Choroidal neovascularization (CNV) is a major cause of visual impairment in patients suf-
fering from wet age-related macular degeneration (AMD), particularly when refractory to
intraocular anti-VEGF injections. Here we report that treatment with the oral miner-
alocorticoid receptor (MR) antagonist spironolactone reduces signs of CNV in patients
refractory to anti-VEGF treatment. In animal models of wet AMD, pharmacological inhibition
of the MR pathway or endothelial-speciﬁc deletion of MR inhibits CNV through VEGF-
independent mechanisms, in part through upregulation of the extracellular matrix protein
decorin. Intravitreal injections of spironolactone-loaded microspheres and systemic delivery
lead to similar reductions in CNV. Together, our work suggests MR inhibition as a novel
therapeutic option for wet AMD patients unresponsive to anti-VEGF drugs.
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Age-related macular degeneration (AMD) is the most fre-quent cause of blindness in the elderly population inindustrialized countries. With a global prevalence of 8%,
the projected number of individuals affected in 2020 is 196 mil-
lion, increasing to 288 million in 20401. Almost a third of early
AMD progresses to neovascular AMD (nAMD). Choroidal neo-
vascularization (CNV), in which new vessels growing from the
choroid toward the neuroretina underneath the macula, causes
macular edema, bleeding, photoreceptors damages, and even-
tually end stage ﬁbrotic scare (Supplementary Fig. 1). Aging,
heredity, diet, smoking, obesity, and vascular diseases are
involved in the pathogenesis of AMD2; however, the exact
mechanisms leading to CNV remain incompletely understood.
CNV is not speciﬁc to AMD, it may complicate multiple other
diseases affecting the retinal pigment epithelium (RPE) and the
choroid, including high myopia and central serous chorior-
etinopathy (CSCR). The pathogenesis of CNV is complex and
multifactorial. Choroidal vessels ensure nutritional and oxygen
supply to the avascular outer retina containing the highly energy
demanding photoreceptor cells. Choriocapillary loss, observed in
nAMD eyes, may cause hypoxia and angiogenesis. A growing
body of evidence also indicates that low-grade inﬂammation,
activation of the inﬂammasome3,4, and alternative complement
pathway activation play key roles in the pathogenesis of nAMD5.
In addition to vascular endothelial growth factor (VEGF) family
members and their receptors6, complement components and pro-
inﬂammatory molecules accumulating in the RPE-choroid com-
plex7, such as cytokines and angiopoietins8, contribute to CNV
growth. The inﬂammation- and hypoxia-induced downregulation
of anti-angiogenic factors such as pigment epithelium-derived
factor (PEDF), endostatin, and thrombospondin-1 (TSP-1)9
favors a pro-angiogenic microenvironment.
Although multiple molecular pathways have been implicated in
the formation and maintenance of CNV, the treatment of nAMD
currently relies on biologic compounds that only neutralize
VEGF, placental growth factor (PlGF), or both without directly
target inﬂammation10,11. Anti-VEGF drugs have strongly
improved the visual prognosis of nAMD, allowing the main-
tenance, and even the restoration of macular function and mor-
phology at the price of multiple intraocular injections12.
However, anti-VEGFs do not allow CNV regression in
nAMD13,14. In addition, they have no effect on the ﬁbrotic
scarring and may compromise long-term choroid and retinal
viability15,16. Instead, anti-VEGF agents regulate vascular per-
meability, as manifested by signs such as edema, which is used to
monitor the need for reinjection17. In >40% of nAMD cases
treated with intensive anti-VEGF treatment for a year, the macula
remains wet, suggesting that other pathways are likely to be
involved18.
Intraocular corticosteroids, a family of potent anti-
inﬂammatory and vasoconstrictor drugs, efﬁciently reduce
macular edema of various origins (diabetic retinopathy, retinal
vein occlusion, intraocular inﬂammation)19–21, but show poor
efﬁcacy in nAMD. Corticosteroids bind to the glucocorticoid
(GR) and mineralocorticoid receptors (MR), both expressed in
the retina and choroid22. We have previously shown that
experimental MR activation mimics CSCR, a retinal disease
induced and aggravated by glucocorticoids and associated with
subretinal ﬂuid accumulation and frequently complicated by
CNV23,24. MR antagonists (MRAs) have been shown to be efﬁ-
cient in CSCR25,26. In the vasculature, the MR expressed in
endothelial and smooth muscle cells contributes to hypertension,
vascular inﬂammation, and ﬁbrosis, for which MRA have bene-
ﬁcial effects27. Glucocorticoids are angiostatic28, whereas miner-
alocorticoids have shown both pro- or anti-angiogenic effects
depending on the experimental model29,30. MRAs showed
various anti-angiogenic effects31, and spironolactone protected
against retinal neovascularization in experimental oxygen-
induced retinopathy32.
Although a growing body of evidence identiﬁes MR as a player
in vascular inﬂammation, ﬁbrosis, and angiogenesis, their role in
the pathogenesis of CNV has not been investigated. In this study,
we show that spironolactone, an oral MRA may reduce signs of
CNV activity in nAMD patients with resistant active CNV despite
monthly intraocular anti-VEGF injections. Using both pharma-
cologic and transgenic approaches in rodents, we show that
antagonism of the mineralocorticoid pathway prevents CNV
through a VEGF-independent mechanism. We ﬁnd that the
beneﬁt of spironolactone is additive with anti-VEGF therapy and
mediated by the regulation of decorin. These pre-clinical and
clinical results identify the MR as a molecular regulatory target
for wet AMD.
Results
Spironolactone reduces CNV activity in refractory nAMD.
Twenty patients with nAMD presenting with refractory intra- or
subretinal ﬂuid despite monthly intravitreal injections of anti-
VEGF (≥12 months anti-VEGF treatment, ≥6 months refrac-
toriness despite monthly injections, using the same anti-VEGF
molecule (Aﬂibercept in 13 eyes/Ranibizumab in 8 eyes),
≥350 µm on thickest A-scan on optical coherence tomography
(OCT)) consented to participate to a prospective pilot study.
Refractoriness was deﬁned as no reduction in exudative signs
during the last 6 months. In addition to monthly injections of
anti-VEGF during the 6-months study period, continuing with
the same anti-VEGF molecule as used during the ≥6 months
before inclusion, they were prescribed adjuvant oral spir-
onolactone (25 mg/day week 1, 50 mg/day until Month 3, 25 mg/
day until Month 4, 0 mg until Month 6). In 21 eyes of 20 patients
with refractory nAMD (13 females, mean age 76.3 ± 7.7 (SD)
years received 37.2 ± 17.1 (mean ± SD) anti-VEGF injections
given over a mean period of 46.0 ± 19.8 (SD) months prior to
study enrollment), statistically signiﬁcant changes in structural
outcome measures, maximal at Month 3 compared to baseline,
were observed on spectral domain OCT (SD-OCT) at various
time points during spironolactone treatment (Fig. 1). The effect
was seen in central retinal thickness (p= 0.011) and volume (p=
0.012), in the foveal thickness (p= 0.039), the thickest cystic
changes (p= 0.040), and subretinal ﬂuid (p= 0.014), which all
quantify macular edema (Table 1 and Fig. 1, using paired Wil-
coxon signed-rank tests). The improvements observed on SD-
OCT were lost after stopping the spironolactone at Month 4
although anti-VEGF injections alone were continued (Table 1 and
Fig. 1). Individual treatment responses are imaged by thickness
maps and a selected B-scan OCT for baseline, 3 and 6 months
(horizontal line) for all eyes, obtained with the follow-up mode of
the Spectralis OCT (Heidelberg Engineering, Germany) (Sup-
plementary Figs. 2–4). There was a high heterogeneity in the
patient’s response to the treatment, with about 50% showing a
reduction of ﬂuid at 3 months that could be attributable to
spironolactone treatment, which without a control groups
remains to be conﬁrmed by a randomized controlled study.
Adjuvant oral spironolactone therapy was subjectively well tol-
erated by most patients. However, two (10%) of them dis-
continued the drug after 2 months due to increased plasma
potassium levels. On the basis of an intention-to-treat approach,
these patients were maintained in the analysis.
Anti-angiogenic effects of MRA in a rat nAMD model. The
above clinical results of anti-edematous effect of MRA might
either be linked to an anti-angiogenic effect on CNV or be an
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anti-edematous effect unrelated to the CNV, as previously
described in other retinal conditions23,26. To test the anti-
angiogenic potential of MRA on CNV, we used an experimental
model induced by laser photocoagulation in rodents, a recognized
model for nAMD33. The argon laser induces a rupture of the
Bruch’s membrane, which separates the RPE from the choroidal
vasculature, leading to the growth of neovessels from the choroid
toward the retina in about 2 weeks. The permeability and size of
CNV were assessed in vivo by ﬂuorescein angiography (FA) at
day 14 and at day 16 after sacriﬁce by ex vivo staining with FITC-
isolectin on choroid ﬂat-mounts. Spironolactone (25 mg/kg/day,
subcutaneous injections from day 0 to day 13) was as efﬁcient as
intravitreal anti-VEGF injection (5 µl at 1.5 µg/µl, at day 0) in
reducing choroidal vascular leakage assessed by angiographic
score and decreasing the volume of the CNV lesions measured on
choroid ﬂat-mounts (Fig. 2a). Co-administration of anti-VEGF
and spironolactone showed an additive effect on neovascular
permeability observed on FA as compared to anti-VEGF alone
(Fig. 2a). Systemic spironolactone inhibited the accumulation of
allograft inﬂammatory factor 1 (IBA1)-positive macrophages/
microglia in the laser burn area (Supplementary Fig. 5a) and
reduced the expression of inﬂammatory cytokines (monocyte
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Fig. 1 Clinical results. a Relative changes in subretinal thickness (SRF, µm) measured with Spectralis OCT during the study period, month 0 (M0) to month
6 (M6). SRF thickness is signiﬁcantly reduced as compared to M0, at M1 (p= 0.012), M2 (p= 0.040), M3 (p= 0.014), M4 (p= 0.024). b Relative change
in central retinal thickness (CRT, µm) automatic values with Spectralis OCT during the study period, month 0 (M0) to month 6 (M6). CRT is signiﬁcantly
reduced as compared to M0, at M3 (p= 0.011), M4 (p= 0.007), and M5 (p= 0.028). At each time point (Month, M), the data have been summarized
using box and whisker plots, the upper and lower 95% CIs (conﬁdence interval) are marked with the whiskers, the box represents the interquartile range,
and the median is represented by the bold horizontal line bisecting the box. Paired Wilcoxon signed-rank tests were used. *p < 0.05
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chemoattractant protein 1 [MCP-1], interleukin [IL] 1β, IL6, and
tumor necrosis factor [TNF]) in the RPE-choroid complexes at
day 3 but had no signiﬁcant effect on the expression of angiogenic
genes such as VEGF, PlGF, ANGPTL4, HIF1α, and TGFβ
(Supplementary Fig. 5b). In the rat ocular media, the VEGF level
was decreased signiﬁcantly by anti-VEGF but not by spir-
onolactone; conversely, the MCP-1 level was decreased by spir-
onolactone but not by anti-VEGF (Supplementary Fig. 5c). These
results demonstrated the effect of pharmacological MR antag-
onism on macrophage/monocytes recruitment. Potential non-
speciﬁc hormonal effects of spironolactone on CNV was excluded
as oral eplerenone (INSPRA®, 200 mg/kg/day, 0.2% in chow), a
more speciﬁc MR antagonist without non-MR related hormonal
side-effects34 had similar anti-angiogenic effects of rat CNV
(Fig. 2b).
To test whether local spironolactone could be as efﬁcient as
systemic administration, we elaborated spironolactone-loaded
poly(lactic-co-glycolic) acid (PLGA) microspheres(MSs), which
can be injected into the vitreous and are well tolerated35. The
mean size of the particles was 21.87 ± 6.84 (SD) µm. Scanning
electron microscopy revealed spherical particles with smooth
surface (Supplementary Fig. 6a). The encapsulation efﬁciency of
spironolactone was 77.03% (128.38 µg spironolactone per mg
MSs) and a constant release rate of 2.35 µg spironolactone per mg
MSs per day was achieved over 31 days (Supplementary Fig. 6a).
A single injection (5 µl of 2.2 µg/µl) of spironolactone-loaded MSs
in the vitreous of rat eyes at day 0 inhibited choroidal neovascular
permeability on FA and signiﬁcantly reduced the volume of CNV
at day 14, as compared to non-loaded-MS-injected eyes
(Supplementary Fig. 6b). Therefore, systemic and local spirono-
lactone showed similar anti-angiogenic effects on rat CNV.
Endothelial MR inactivation reduces CNV in mice. To identify
the cellular targets of MRAs, we evaluated the expression and
localization of MR in the retinas of rat eyes developing CNV. MR
expression was upregulated in the neural retina and in the RPE-
choroid complex at day 3 after laser induction, and returned to
the basal level at day 16, the late phase of CNV (Supplementary
Fig. 7a). Immunohistochemistry showed that the MR was
expressed not only in the ganglion cell layer, the inner nuclear
layer, the RPE and endothelial cells as described previously22,23,
but also in the inﬁltrating cells and in neovascular components
within subretinal spaces surrounding the laser burns (Supple-
mentary Fig. 7b–d, arrows). To determine which cell types could
drive the MR-induced angiogenic signals, we used conditional
transgenic models lacking a functional MR in speciﬁc cell types.
Speciﬁc conditional ablation of MR in endothelial cells only
(Vecadh-MR-KO) signiﬁcantly reduced CNV on FA and on
choroidal ﬂat-mounts (Fig. 3b), demonstrating that endothelial
cells drive MR-induced angiogenesis. This ﬁnding was further
conﬁrmed in another ocular model of angiogenesis, in which
neovessel growth is induced in the avascular cornea by corneal
de-epithelialization. In this model, angiogenesis was also sig-
niﬁcantly impaired in Vecadh-MR-KO mice (Fig. 3c), suggesting
a broader angiogenic effect of the endothelial MR. Of note, tar-
geted MR inactivation in smooth muscle cells (SMA-MR-KO
mice) or in granulocytes and macrophages (Lys-MR-KO mice)
has no effect on the development of CNV (Supplementary Fig. 8a,
b), conﬁrming the endothelial cell speciﬁcity of the MR function
in angiogenesis. To validate this ﬁnding, we used another trans-
genic model in which MR is constitutively deleted under the
endothelial Tie2 promoter (Tie2-MR-Ko), expressed both in
endothelial cells and in myeloid cells36. Using the laser-induced
Table 1 Functional and structural outcome measures in nAMD patients treated with spironolactone
Month 0 Month 1 Month 2 Month 3 Month 4 Month 5 Month 6
Intake of spironolactone before presentation - 50mg 50mg 50mg 25mg - -
New prescription of spironolactone 25mg/50
mg
50mg 50mg 25mg 0mg 0mg End of study
Intravitreal anti-VEGF injections Monthly Monthly Monthly Monthly Monthly Monthly Monthly
Mean maximum retinal thickness [ILM to
Bruch’s membrane (µm)]
539 ± 134 523 ± 153
(p= 0.10)
517 ± 148
(p= 0.08)
484 ± 154
(p=
0.042*)
487 ± 151
(p= 0.056)
500 ± 153
(p= 0.15)
503 ± 158
(p= 0.20)
Mean best-corrected visual acuity (ETDRS
letters ± SD)
72.8 ± 12.2 72.5 ± 12.4
(p= 0.96)
72.0 ± 13.8
(p= 0.72)
70.8 ± 13.8
(p= 0.48)
71.4 ± 13.2
(p= 0.68)
73.0 ± 9.8
(p= 0.46)
72.0 ± 11.6
(p= 0.96)
Mean central retinal thickness [automatic
values from SD-OCT (µm) ± SD]
340 ± 65 332 ± 84
(p= 0.38)
326 ± 86
(p= 0.32)
311 ± 81
(p= 0.011*)
307 ± 84
(p=
0.007*)
312 ± 87
(p=
0.028*)
322 ± 89
(p= 0.18)
Mean central retinal volume [automatic values
from SD-OCT (mm3) ± SD]
0.268 ±
0.052
0.263 ±
0.066
(p= 0.48)
0.255 ±
0.069
(p= 0.28)
0.244 ±
0.064
(p= 0.012*)
0.242 ±
0.066
(p=
0.010*)
0.245 ±
0.068
(p=
0.032*)
0.252 ±
0.070
(p= 0.18)
Mean foveal retinal thickness [ILM to RPE
(µm)]
407 ± 161 384 ± 164
(p= 0.063]
377 ± 152
(p=
0.039*)
344 ± 148
(p=
0.039*)
345 ± 151
(p=
0.049*)
354 ± 159
(p= 0.088)
355 ± 162
(p= 0.099)
Mean of the maximum neuroretinal thickness
with cystic changes [ILM to outer segments of
photoreceptors (µm)]
329 ± 172 308 ± 166
(p= 0.16)
295 ± 160
(p=
0.041*)
288 ± 155
(p=
0.040*)
293 ± 160
(p= 0.010)
304 ± 169
(p= 0.19)
300 ± 164
(p= 0.17)
Mean subretinal ﬂuid thickness [between outer
segment layer and pigment epithelium (µm)]
107 ± 74 86 ± 78
(p=
0.012*)
74 ± 58
(p=
0.040*)
58 ± 61
(p=
0.014*)
70 ± 63
(p=
0.024*)
87 ± 80
(p= 0.33)
90 ± 75
(p= 0.29)
Mean pigment epithelium detachment height
[(RPE layer to Bruch’s membrane (µm)]
266 ± 139 266 ± 144
(p= 0.93)
266 ± 146
(p= 0.87)
244 ± 153
(p= 0.27)
245 ± 160
(p= 0.34)
248 ± 159
(p= 0.40)
254 ± 160
(p= 0.54)
Mean subfoveal choroidal thickness [(µm)
measured using EDI OCT]
202 ± 87 207 ± 95
(p= 0.33)
203 ± 97
(p = 0.70)
203 ± 92
(p= 0.67)
205 ± 91
(p= 0.58)
203 ± 95
(p= 0.69)
204 ± 94
(p= 0.69)
Patients received spironolactone as add-on treatment to monthly anti-VEGF injections
SD standard deviation, ILM internal limiting membrane, RPE retinal pigment epithelium, EDI enhanced depth imaging, OCT optical coherence tomography, SD-OCT spectral domain OCT, VEGF vascular
endothelial growth factor
All p-values are calculated by comparisons with baseline values using paired Wilcoxon signed-rank tests. *, p < 0.05
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Fig. 2 Spironolactone and eplerenone reduce CNV in a rat nAMD model. a Spironolactone (Spiro) signiﬁcantly reduces the CNV angiographic grades
evaluated on ﬂuorescein angiography (FA) (p= 0.0025) and the CNV volume labeled with FITC-isolectin (green) (p= 0.002) as compared to the control
group (Ctrl). Infrared images (IR) are used to localize and check the efﬁcient laser-induced burns. The effect of spironolactone is not different from anti-
VEGF in reducing the choroidal neovascular leakage on FA and inhibiting the CNV in rat choroidal ﬂat-mounts. Combining the two treatments allows an
enhanced effect in reducing vascular permeability compared to anti-VEGF alone (p= 0.0335). b Eplerenone, a more speciﬁc MR antagonist, given orally,
signiﬁcantly reduces CNV angiographic grades (p= 0.0012) and CNV volumes (p < 0.0001). Bars: 100 µm. FA Data are expressed as the incidence of CNV
angiographic grades of the total laser impacts in each group. CNV volumes are expressed as mean ± SEM of average CNV size per rat. n represents the
number of rats. Linear mixed model was used for statistical analyses. *p < 0.05, **p < 0.01, ***p < 0.001
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nAMD model, the angiographic score and the CNV volume were
also reduced in Tie2-MR-KO mice (Supplementary Fig. 8c),
however, the effect was not signiﬁcantly different from that
observed in Vecadh-MR-KO mice (p= 0.1740, repeated measures
linear mixed model), suggesting that myeloid MR is not essential
in laser-induced CNV. In addition, systemic treatment with
spironolactone (Fig. 3a), which antagonizes MR in all cells did not
result in a more potent anti-angiogenic effect in mice as com-
pared to the effect observed in Vecadh-MR-KO mice (p= 0.5507,
repeated measures linear mixed model). Lack of effect on CNV in
SMA-MR-KO, which is tamoxifen-inducible, eliminates a
potential non-speciﬁc effect of Cre with tamoxifen. A non-speciﬁc
effect of tamoxifen alone was eliminated since control mice
received tamoxifen when used to activate the Cre recombinase in
the Vecadh-MR-KO mice, and because in the Tie2-MR-KO mice,
which is not tamoxifen-inducible, the reduction in CNV was not
higher than in the Vecadh-MR-KO mice. Taken together, these
results suggest that endothelial MR is required for the develop-
ment of CNV.
Decorin mediates angiogenic effect of endothelial MR in CNV.
Among the potential molecular targets of the MR in the endo-
thelial cells that could regulate angiogenesis, decorin (DCN) was
selected from a full transcriptomic approach designed to identify
genes regulated by aldosterone in the whole rat retina consisting
of neural retina and RPE-choroid complex (Supplementary
data 1). The expression of DCN messenger RNA (mRNA),
encoding a matrix protein of the member of the small leucine-
rich proteoglycan family, was down-regulated by approximately
2.64 times in the transcriptome of the rat whole retina injected
with aldosterone (20 nM ﬁnal vitreous concentration) compared
with that of the vehicle-injected one (Supplementary Data 2). In
the rat CNV model, DCN protein expression was reduced in the
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Fig. 3 Vascular endothelial MR contributes to CNV. a Systemic spironolactone signiﬁcantly reduces CNV ﬂuorescein angiographic (FA) grades (p < 0.001)
as well as CNV volume (p= 0.0348) as compared to control mice. CNV were labeled with FITC-dextran (green). Infrared (IR) images show up all the laser
burns in the fundus. b Cell-type-speciﬁc MR deletion from endothelial cells using the VE-Cadherin promoter (Vecadh-MR-KO) reduces CNV leakage on FA
(p= 0.0041) and decreases the volume of CNV labeled with FITC-dextran (green) in mice (p= 0.0434). IR images show up all the laser burns. Bar:
100 µm (a, b). FA Data are expressed as the incidence of CNV angiographic grades of the total laser impacts in each group. CNV volumes are expressed as
mean ± SEM of the average CNV size per mouse. n represents the number of mice. Linear mixed model was used for statistical analyses. *p < 0.05. c In a
model of corneal neovascularization using Vecadh-MR-KO mice, a reduction in corneal neovessels labeled with FITC-dextran was observed compared to
control mice. Quantiﬁcation of the neovascular surface on mosaic images conﬁrms a signiﬁcant decrease in the neovascularization/whole corneal area
ratio in Vecadh-MR-KO mice. Data are expressed as mean ± SEM. n represents the number of mice. Non-parametric Mann–Whitney U-test was used.
**p < 0.01
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RPE-choroid as early as 3 days after CNV induction (Fig. 4a)
consistent with the timing of MR upregulation in the RPE-
choroid (Supplementary Fig. 7a). The DCN levels partly recov-
ered from day 7 to day 10 (Fig. 4a), suggesting that decreased
DCN might contribute to the pro-angiogenic balance in this CNV
model. To analyze the anti-angiogenic effect of DCN in CNV, we
used a recombinant mouse DCN protein that shares 87% amino-
acid sequence identity with rat DCN. Intravitreous injection of
recombinant mDCN was performed after laser induction at an
estimated ﬁnal concentration of 1 µg/ml or 10 µg/ml in rat
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Kinetics of DCN in RPE-choroid
during CNV
Fig. 4 Spironolactone inhibits CNV through induction of anti-angiogenic decorin protein. a On western blot, the decorin (DCN) level decreases in the rat
retinal pigment epithelium (RPE)-choroid at different time point (day 1, 3, 7, and 10) after laser induction compared to the normal rat RPE-choroid (ctrl).
Densitometric quantiﬁcation shows signiﬁcant decrease of DCN protein in rat RPE-choroid at day 3 after laser induction. b Intravitreal injection (IVT) of
recombinant mDCN protein in rat eyes inhibits choroidal vascular leakage on ﬂuorescein angiography (FA); DCN 10 µg/ml signiﬁcantly reduces the CNV
angiographic grades (p= 0.02), whereas DCN at both 1 µg/ml (p= 0.0461) and 10 µg/ml (p= 0.0388) decrease the size of CNV induced by laser. c IVT
of DCN siRNA in rat eyes with laser-induced CNV. Treatment with spironolactone (Spiro) in the presence of control siRNA signiﬁcantly increases the DCN
protein level in the rat RPE-choroid 48 h after laser induction. IVT of DCN siRNA prevents the increase in the DCN protein induced by spironolactone.
d Treatment with spironolactone in the presence of control siRNA inhibits choroidal neovascular leakage on FA at day 14 after laser induction (p= 0.0194).
IVT of DCN siRNA at day 0 and 3 after laser induction abrogates the effect of spironolactone on vascular leakage (p= 0.0344). Spironolactone in the
presence of control siRNA reduces signiﬁcantly CNV volume as compared to laser control (p < 0.0001). DCN siRNA injected at day 0 and 3 after laser
induction abrogates the effect of spironolactone on CNV volume (p= 0.0003). Western blot data are expressed as mean ± SEM. Dots represent individual
RPE-choroid sample. Non-parametric Kruskal–Wallis test was used. FA Data are expressed as the incidence of CNV angiographic grades of the total laser
impacts in each group. CNV volumes are expressed as mean ± SEM of the average CNV size per rat. n represents the number of rats. Linear mixed model
was used for statistical analyses. *p < 0.05, **p < 0.01, ***p < 0.001
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vitreous. At day 14, eyes treated with recombinant mDCN at
10 µg/ml showed reduced choroidal vascular leakage (Fig. 4b).
The CNV volume was decreased signiﬁcantly by DCN at both 1
µg/ml and 10 µg/ml (Fig. 4b), conﬁrming a major role of DCN in
inhibiting CNV proliferation and leakage. In the rat nAMD
model, DCN expression and protein were reduced at day 3 after
laser induction and spironolactone upregulated the DCN tran-
scripts (Supplementary Fig. 9a) and the DCN protein levels
(Supplementary Fig. 9b) in the rat RPE-choroid, suggesting that
the anti-angiogenic effect of spironolactone could be mediated by
DCN expression. To test this hypothesis, we designed a strategy
to interfere with the effect of spironolactone on DCN expression.
We co-administered systemic spironolactone with intraocular
siRNA directed against DCN. Spironolactone (in the presence of
scrambled siRNAs) signiﬁcantly prevented the laser-induced
decrease in DCN protein at day 2 following induction (Fig. 4c).
In contrast, DCN siRNA inhibited the DCN upregulation by
spironolactone (Fig. 4c), conﬁrming its efﬁciency in DCN
knockdown. We next tested whether abrogation of the DCN
upregulation induced by spironolactone could clinically reduce
the anti-angiogenic effect of spironolactone. Rats were treated
daily with spironolactone and injected intravitreously with
scrambled or DCN siRNA at day 0 and day 3. At day 14, co-
administration of spironolactone and DCN siRNA abolished the
effect of spironolactone on choroidal neovascular permeability as
estimated by FA (Fig. 4d) and reduced the CNV volume (Fig. 4d),
demonstrating that DCN mediates, at least in part, the anti-
angiogenic effect of spironolactone.
Taken together, these results show that the clinical effect of
spironolactone on nAMD refractory to anti-VEGF can be
explained by a direct antagonism of the MR in endothelial cells,
leading to DCN overexpression.
Discussion
Anti-VEGF therapy has revolutionized the visual prognosis of
CNV, in particular in nAMD patients, from rapid progression to
central blindness to central vision stabilized or even improved
for several years12, demonstrating the key role of VEGF in the
regulation of hydro-ionic retinal homeostasis and vascular per-
meability37. However not all nAMD patients respond well to
anti-VEGF treatment, particularly when CNV develops under-
neath the detached retinal pigment epithelium, which represents
more than 50% of CNV in AMD cases (Type 1 CNV)38,39 and
complicates 30–40% of chronic CSCR cases. Moreover, in
around 50% of nAMD patients, depending on the drug and
regimens, ﬂuid retention persists in the macula despite optimal
anti-VEGF treatments18,40. Anti-platelet-derived-growth-factor
(PDGF) therapies failed to demonstrate synergistic effects with
anti-VEGFs in 2 phase-3 clinical trials41, and no other ther-
apeutic options are currently available for nAMD patients not
responding optimally to anti-VEGFs. In our clinical pilot study,
despite long-lasting anti-VEGF-resistant macular edema,
patients treated orally with the MRA spironolactone for
4 months while continuing monthly injection of the same anti-
VEGF treatment, showed a signiﬁcant reduction in signs of CNV
activity as measured by FA and SD-OCT. Notably, the effect was
lost when spironolactone was stopped, demonstrating that the
clinical improvement was an effect of the spironolactone. Despite
anatomical improvement, no immediate effect on visual acuity
was observed in this group of chronic nAMD patients, which
could be due to disease chronicity and irreversible lesions and/ or
the short duration of treatment, or sub optimal route of
administration. In a recent retrospective study without a control
group or controlled time after MRA application, a beneﬁcial
effect of MRA on subretinal ﬂuid absorption in anti-VEGF
refractory nAMD was also reported42. Whether the MRA acted
on ﬂuid reabsorption only or also on neovessels could not be
determined.
No animal model recapitulates all nAMD features, and the
common laboratory animals have no macula. However, laser-
induced CNV models in rodents and primate are validated in
screening anti-angiogenic drugs for nAMD33. In the present
study, the MRA spironolactone administrated systemically in rats
was as efﬁcient as the reference intravitreal anti-VEGF drug for
suppressing CNV. Eplerenone, a more speciﬁc MR antagonist,
given orally, also efﬁciently reduced rat CNV, supporting the
speciﬁc role of MR pathway activation in choroidal neovascu-
larization. Spironolactone signiﬁcantly inhibited the development
of CNV in rats without affecting the ocular VEGF levels; however,
MCP-1 expression and microglia/macrophage inﬁltration at the
site of CNV, both known contributors to CNV in AMD43,44, were
reduced. The monocyte-expressed MR has been reported to sti-
mulate pro-inﬂammatory macrophages45,46. However, MR dele-
tion speciﬁcally in myeloid cells did not prevent CNV, and MR
deletion in both endothelial cells and myeloid cells did not show a
superior inhibitor effect on CNV as compared to MR deletion in
endothelial cells only, demonstrating that the beneﬁt of MRA in
CNV is not primarily mediated by MR modulation of the mac-
rophage phenotype. In contrast, speciﬁc deletion of the MR in
endothelial cells signiﬁcantly inhibited choroidal and corneal
neovascularization, indicating that MR activation is pro-
angiogenic in wound healing. In addition, systemic spir-
onolactone treatment in mice, which antagonizes all MR
expressing cells, did not exert superior anti-angiogenic effect than
the deletion of MR speciﬁcally in endothelial cells (Vecadh-MR-
KO). Similar anti-angiogenic effects of spironolactone have been
reported in a model of oxygen-induced retinopathy in which
neovessels develops from the retinal vasculature32.
The search for molecular pathways regulated by MR potentially
modulating angiogenesis and inﬂammation led us to identify
DCN47as a potential mediator of the MR effect. In fact, DCN was
downregulated in the retina and RPE-choroid complex of
aldosterone-injected rats. Furthermore, we showed an anti-
angiogenic effect of DCN on CNV. Importantly, laser-induced
CNV decreased DCN expression in the RPE-choroid, and this
effect was prevented by spironolactone treatment. In addition, a
DCN siRNA suppressed the anti-angiogenic effect of spir-
onolactone, identifying DCN as a novel molecular target of
spironolactone. In the healthy human eye, DCN is strongly
expressed in the cornea, where it intervenes in ﬁbrillogenesis and
tissue repair48. In the retina, DCN has been identiﬁed to be
located in all layers but is particularly abundant in Bruch’s
membrane, which separates the RPE from the choroid, and in the
choroid itself49. As a component of the extracellular matrix, DCN
can modulate angiogenesis through interaction with numerous
molecules47,50. In corneal wound healing models and in inﬂam-
matory angiogenesis, DCN is anti-angiogenic51,52. This effect
results from the sequestration of growth factors such as TGF-β,
an antagonism of tyrosine kinase family receptors including the
VEGF-R250,53, and stimulation of angiostatic molecules such as
thrombospondin and tissue inhibitor of metalloproteinase 3
(TIMP3)54. Under hypoxic conditions, DCN reduced choroidal
endothelial cell proliferation induced by the RPE in culture55. In
addition, DCN exerts an anti-inﬂammatory effect through a
decrease in macrophage proliferation56 and recruitment, in turn
mediated by MCP-1 downregulation57. In mice CNV, DCN
inhibited TGFβ-induced smad2/3 pathway58. DCN expression in
relation to AMD has not been studied speciﬁcally; however, a
quantitative proteomic analysis of Bruch’s membrane/choroid
from AMD eyes showed signiﬁcantly decreased DCN levels
compared to those in healthy controls59. In addition, DCN
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expression was reduced by approximately 20% in advanced wet as
compared to advanced dry AMD eyes59, supporting a role for
DCN in wet AMD.
In the retina, experimental MR activation has been shown to be
pathogenic leading to choroidal vessel dilation, leakage and
subretinal ﬂuid retention (mimicking CSCR)23, retinal edema
mediated by glial hydro-ionic deregulation22 and retinal neo-
vascularization in a model of retinopathy of prematurity32. In the
rodent retina, MR and hydroxysteroid dehydrogenase type 2 are
co-expressed in several cell types but not all suggesting that MR
pathway could thus be activated by both gluco and miner-
alocorticoids23. Based on clinical observations, MRAs are cur-
rently used to reduce edema in CSCR24,60. In the present study,
we demonstrated that MR activation in vascular endothelial cells
contributes to CNV, which is also frequently associated with
CSCR. The MR pathway may thus be a common mechanism
involved in CNV development in AMD and in CSCR. Why MR is
hyper-activated in these conditions is not fully understood. In
most organs, the MR are occupied by glucocorticoids, prevalent
in the plasma over aldosterone61. In nAMD, MR activation may
explain the poor efﬁcacy of glucocorticoids on CNV11, with their
potent anti-inﬂammatory effects being overridden by the pro-
edematous and pro-angiogenic MR pathway. Further studies are
required to analyze the MR/GR pathway in AMD.
Local delivery is the method of choice for ocular diseases, allowing
higher ocular drug levels without systemic side-effects. For this
purpose, slow-release drug delivery systems are mandatory to reduce
the frequency of ocular injections. The pre-clinical tolerance of our
polymeric spironolactone MS formulation has been demonstrated
previously35 offering a basis for further clinical testing.
In conclusion, our clinical and experimental data demonstrate
that vascular MR activation contributes to CNV. In a pilot study,
including patients with refractory and long-lasting exudative
signs despite anti-VEGF treatment, we showed that MRA might
have an effect on intra and/ or subretinal ﬂuid. In addition, our
experimental data support that MR pathway activation con-
tributes to the pathogenesis of nAMD through a VEGF-
independent pathway related to DCN, which represents a ther-
apeutic target for nAMD. Further randomized clinical trials,
optimally using ocular dedicated formulations, are required to
evaluate the therapeutic potential of MR pathway blockade in
patients with refractory nAMD.
Methods
Patients. A prospective clinical pilot study was performed to evaluate in vivo the
effect of spironolactone, an oral MRA, in patients with exudative signs of nAMD.
This study was approved by the local ethics committee (#184/14 ethical committee
approval, Canton de Vaud), and performed following the regulations of the
mentioned committees. It adhered to the Declaration of Helsinki for human
research. Informed consent was obtained from all human participants. This study
has been retrospectively registered on 16 November, 2018 under the registration
number NCT03744767.
Only patients with refractory stable intraretinal or subretinal ﬂuid present for
≥6 months in a row on monthly SD-OCT despite monthly intravitreal of the same
anti-VEGF treatment (ranibizumab or aﬂibercept) were included. The total
duration of anti-VEGF treatment before inclusion in the study was required to
be ≥12 months to avoid the effect of improvement due to treatment initiation. The
thickest macular A-scan from the inner limiting membrane to the RPE band was
required to be ≥ 350 µm. Patients giving informed consent were included from
September 2014 to March 2015.
The exclusion criteria were polypoidal choroidal vasculopathy, poor imaging
quality of the fundus, or any contra-indication to systemic spironolactone (arterial
pressure >160/100, K+ >5.0 mmol/l, Na+ <135 mmol/l, calculated creatinine
clearance under 30 ml/min [coefﬁcient × {140-age} × weight/serum creatinine;
coefﬁcient= 1.23 for males and 1.04 for females], acute renal failure, renal dialysis,
unspeciﬁed renal problem, arrhythmia, cardiovascular polymorbidity with
thromboembolic risk, known hypersensitivity to spironolactone, ongoing treatment
with epleronone, and decompensated hepatic cirrhosis). The treating physician was
informed and potentially interacting medications were discussed. During the
6 months study, participants continued ﬁxed monthly intravitreal injections of the
same anti-VEGF drug as before, and were prescribed adjunctive oral
spironolactone for 4 months (25 mg/day in week 1, then 50 mg/day until Month 3,
decreasing to 25 mg/day during Month 4, then stopped) and followed off
spironolactone until Month 6. Safety monitoring included history taking for
adverse events, arterial blood pressure and laboratory analysis for changes in serum
levels of K+ , Na+ , creatinine, and urea. In case of clinically signiﬁcant changes,
the investigator was allowed to reduce the dosage of spironolactone. At each
monthly follow-up visit during the 6 months study, the best-corrected visual acuity
(as determined by the Early Treatment Diabetic Retinopathy Study [ETDRS] test
score) was recorded and SD-OCT was performed using the follow-up mode. The
SD-OCT cubes included 49 horizontal B-scans, encompassing a 6 × 6 mm retinal
area, centered on the CNV lesion. The predetermined primary endpoint was the
retinal thickness change from baseline to Month 4 (end of adjunctive
spironolactone treatment) at the site of maximum retinal thickness (from internal
limiting membrane to Bruch’s membrane) measured at baseline and each follow-
up visit on the identical A-scan using the inbuilt Spectralis follow-up software.
Secondary endpoints included the change in maximum retinal thickness from
month 4 to month 6 (anti-VEGF only), and changes in visual acuity (ETDRS
letters), automated central retinal thickness (CRT) measurements, automated
central retinal volume, the foveal retinal thickness, subretinal ﬂuid, neuroretinal
thickness, pigment epithelium detachment height, and choroidal thickness at each
monthly evaluation time points.
All quantitative follow-up parameters were statistically analyzed and compared
with the baseline parameters using paired Wilcoxon signed-rank tests. For data
analysis, Microsoft Excel 2010 and JMP software for Windows (version 8.0.1, SAS
Institute Inc., Cary, NC) were used. A two-tailed probability of 0.05 or less was
considered statistically signiﬁcant. The required study sample size was estimated
before study initiation. According to the available literature on CSCR, and
assuming that the treatment would be less effective in eyes with nAMD, our goal
was to examine whether spironolactone could produce a minimum decrease of 15%
in all measured retinal thicknesses. Therefore, to achieve a 90% power for detecting
this degree of change, we estimated that 21 eyes would be required.
Microsphere elaboration. PLGA ratio 50:50 (Resomer®503) was purchased from
Boehringer Ingelheim Pharma GmbH & Co. (Ingelheim, Germany). Spir-
onolactone was obtained from Sigma-Aldrich (Schnelldorf, Germany). Polyvinyl
alcohol 72,000 g/mol (PVA) was obtained from Merck KGaA (Darmstadt, Ger-
many). All organic solvents were high performance liquid chromatography
(HPLC) grade and used as received.
Spironolactone-loaded and non-loaded PLGA MSs were elaborated using an
oil-in-water (O/W) emulsion solvent evaporation technique35. Brieﬂy, The O-
phase was prepared by suspension of 40 mg of spironolactone in 1 ml of PLGA
solution in methylene chloride (20% w/v) resulting in a Spiro:PLGA ratio of 2:10.
This phase was emulsiﬁed with the W-phase composed by 5 ml of PVA MilliQ®
water solution (2% w/v). The emulsiﬁcation was performed at 5,000 rpm for 1 min
(Polytron® RECO, Kinematica GmbH PT 10–35, Lucerna, Switzerland). This O/W
emulsion was subsequently poured onto 100 ml of an aqueous PVA solution (0.1%)
and maintained under constant stirring for 3 h to allow MSs hardening. After that,
the MSs were washed, ﬁltered, freeze-dried, and kept at −20 °C under dry
conditions until used.
Microsphere characterization. Production yield percentage (PY%) was calculated
as the percentage of MS weight divided by the total amount of PLGA and spir-
onolactone initially used in the formulation process.
PY%= (weight of microspheres/initial amount of PLGA and spironolactone) ×
100
The mean particle size and particle size distribution were measured in aqueous
suspension by light scattering in a Microtrac® S3500 Series Particle Size Analyzer
(Montgomeryville, PA, USA).
The external morphology of MSs was evaluated by scanning electron
microscopy (Jeol, JSM-6335F, Tokyo, Japan). Particles were gold sputter-coating
for observation.
Spironolactone quantiﬁcation. For in vitro characterization, spironolactone was
quantiﬁed by HPLC35. Encapsulation efﬁciency of spironolactone in the micro-
spheres was determined as follows: 5 mg of MSs were dissolved in methylene
chloride (1 ml). After that, the polymer was precipitated by addition of 4 ml of
ethanol. The polymer suspension was vortex mixing and centrifuged (8500 x g;
5 min). The supernatant was recovered and ﬁltered (0.22 µm) for drug quantiﬁ-
cation by HPLC.
In vitro release studies were performed using 18 samples, which were prepared
by suspension of 5 mg spironolactone-loaded MSs in 1.8 ml of release medium
(phosphate buffered saline pH 7.4 isotonic with NaCl). Samples were kept at 37 °C
under constant agitation at 100 rpm (Clifton Shaking Bath NE5, Nikel Electro Ldt,
Avon, UK). At pre-set time point (4, 7, 11, 14, 18, 21, 25, 28, and 31 days) all the
samples were centrifuged (8500 x g; 3 min; 20 °C). At each time point, two of the
pellets obtained after centrifugation were frozen and freeze-dried. The amount of
the drug remaining in the particles was quantiﬁed from the obtained powders using
the same protocol described for encapsulation efﬁciency and the amount of
released drug was calculated as the difference between the initial content and the
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actual content at each time point. The rest of the supernatants were removed and
replaced with the same volume of fresh medium, to continue the release test.
Animals. All experiments were performed in accordance with the European
Communities Council Directive 86/609/EEC and French national regulations and
approved by local ethical committees (#2541–2015110210279792 v3, Charles
Darwin). Six to eight-week old male Long Evans rats from the Janvier Breeding
Center (Le Genest-Saint-Isle, France) were used to create a rat model of CNV.
Three-month old male mice with cell-type-speciﬁc MR deletion in endothelial,
smooth muscle and myeloid cells, (i.e., Vecadh-MR-KO, Tie2-MR-KO, SMA-MR-
KO and Lys-MR-KO mouse models, respectively), were generated in the C57BL/6
genetic background as previously described62–64. Floxed MR (MRf/f) mice65
(kindly provided by Dr. Berger, Heidelberg, Germany) were crossed with mice
expressing an inducible Cre-ERT2 recombinase driven by the VE-Cadherin pro-
moter (Cdh5(PAC)-Cre-ERT2 line, kindly provided by Prof. Adams, London,
UK;66 to generate Vecadh-MR-KO mice) or by the -SMA promoter67 (kindly
provided by Dr. Metzger, Strasbourg, France; to generating SMA-MR-KO mice).
Cell-speciﬁc MR inactivation was induced by tamoxifen injection (1 mg/day in
corn oil for 5 consecutive days) 14 days before experiments and CNV induction.
Both KO and control mice received same tamoxifen regimen.
Lys-MR-KO mice were obtained by mating mice expressing Cre recombinase in
myeloid cells (LysMcre;63 The Jackson Laboratory, USA) with the ﬂoxed MR mice.
MRf/f littermates lacking the Cre transgene were used as controls.
Floxed MR mice were crossed with Tie2-Cre mice (strain: B6.Cg-Tg(Tek-cre)
12Flv/J, The Jackson Laboratory) to obtain EC MR-/- (MRﬂox/ﬂox//Tie2-Cre)
mice and corresponding MR f/f littermates as controls.
Animals were kept in pathogen-free conditions with food, water and litter, and
housed in a 12-h light/12-h dark cycle. Anesthesia was induced by intramuscular
ketamine 40 mg/kg and xylazine 4 mg/kg in rats, and intraperitoneal injection of
ketamine 50 mg/kg and xylazine10 mg/kg in mice. Animals were sacriﬁced by
carbon dioxide inhalation or cervical dislocation.
Model of corneal neovascularization. Vecadh-MR-KO mice and their MRf/f
littermates were used for the generation of corneal neovascularization. Only the
right eye of each animal was used. The corneal epithelium was entirely removed up
to the limbus with a surgical microsponge imbibed with 70% alcohol. A suture
(7–0 silk) was made to maintain the eyelids closed until day 3. At day 10, mice were
perfused with 200 µl FITC-dextran (5 mg/ml, molecular weight 2,000,000, Sigma-
Aldrich FD2000S, St-Quentin Fallavier, France) before sacriﬁce and enucleation.
Eyes were then ﬁxed in 4% paraformaldehyde (PFA) for 2 h and washed in
phosphate buffered saline (PBS). Corneal buttons were dissected and ﬂat-mounted.
FITC-dextran perfused corneal neovessels were observed with a ﬂuorescence
microscope (Olympus, Rungis, France). A mosaic of pictures and quantiﬁcation
were obtained using ImageJ. The area of neovascularization was expressed as a
percentage of the total corneal area.
Laser-induced CNV. After anesthesia and dilation of the pupils, coverslips were
positioned on the cornea as a contact glass. For rats, six or eight burns (six burns in
rat eyes used for ﬂuorescein angiography and CNV quantiﬁcation; eight burns in
rat eyes used for QPCR and western blot analyses) were performed 2 to 3 optic disc
diameters away from the optic nerve with an Argon laser (532 nm) mounted on a
slit lamp (175 mW, 0.1 s, and 50 µm). For mice, four laser burns were induced at
the 3, 6, 9 and 12 o’clock positions around the optic disc (250 mW, 0.05 s, and
50 µm). Both eyes of animals received laser induction. The presence of a bubble
witnessed the rupture of Bruch’s membrane and conﬁrmed a successful laser
impact.
Treatments. Treatments were introduced in the rat model of CNV. After laser
photocoagulation, rats were divided into eight treatment groups: (1) daily sub-
cutaneous injection of spironolactone diluted in 90% olive oil and 10% dimethyl
sulfoxide (DMSO) (25 mg/kg/day) until sacriﬁce; (2) daily subcutaneous injection
of vehicle (olive oil+DMSO) until sacriﬁce; (3) intravitreous injection (IVT) of
anti-rat VEGF (5 µl of 1.5 µg/µl, RnD system, Lille, France) at day 0; (4) co-
administration of subcutaneous spironolactone with anti-VEGF IVT; (5) IVT of
spironolactone-loaded PLGA MSs at day 0 (5 µl of 2.2 µg/µl); (6) IVT of non-
loaded PLGA MSs (5 µl) at day 0; (7) Oral eplerenone (INSPRA®, 200 mg/kg/day,
0.2% in chow) from day 0 until sacriﬁce; (8) Control normal chow from day 0 until
sacriﬁce. Wild-type C57BL/6 mice were also treated with daily subcutaneous
injection of spironolactone (50 mg/kg/day) from day 0 to sacriﬁce, compared to
vehicle injections (olive oil+DMSO).
Fluorescein angiography (FA). FA was performed 14 days (in rats) or 10 days (in
mice) after laser induction. After pupil dilatation, ﬂuorescein (0.2 ml of 10%
ﬂuorescein in saline) was injected intravenously in the tail of rats, or intraperitoneal
(0.1 ml) in mice. Early and late phase angiograms were recorded at 1–3 and 5–7
min, respectively, after ﬂuorescein injection. Simultaneously, infrared images were
acquired to detect the site and effective presence of laser burn. For each laser-
induced lesion, ﬂuorescein leakage was graded qualitatively by evaluating the
increase in size/intensity of dye between the early and late phases. Angiographic
scores were established by two blinded observers according to the following cri-
teria: grade 0, no hyperﬂuorescence; grade 1, slight hyperﬂuorescence with no
increase in intensity nor in size; grade 2, hyperﬂuorescence increasing in intensity
but not in size; grade 3, hyperﬂuorescence increasing both in intensity and size;
grade 4, hyperﬂuorescence size increase more than 2-diameter of the initial laser
burn.
RPE-choroid ﬂat-mounts and CNV quantiﬁcations. Two days after FA exam-
ination (time necessary for ﬂuorescein elimination), eyes were enucleated, ﬁxed in
4% PFA for 15 min at room temperature and sectioned at the limbus; the cornea
and lens were discarded. The retina was separated from the RPE-choroid complex.
Eight radial incisions were made on the RPE-choroid, which was then ﬂat-mounted
and post-ﬁxed with acetone for 15 min at −20 °C. After washing with 0.1% Triton
x100 in PBS, FITC-GSL I-Isolectin B4 (FL-1201, 1:200, Vector, AbCys, Paris,
France) was applied overnight at −4 °C. After washing with PBS, the RPE-choroid
was ﬂat-mounted and observed with a confocal microscope (Zeiss LSM710, Le
Pecq, France). Images of the CNV were captured with a digital video camera
coupled to a computer system. Bruch ruptures could be easily observed at each
laser spot. Horizontal optical sections (at 1 µm intervals) were obtained from the
CNV surface. The deepest focal plane in which the surrounding choroidal vascular
network connecting to the lesion could be identiﬁed was judged to be the ﬂoor of
the CNV lesion. The area of CNV-related ﬂuorescence on each horizontal section
was measured using the ImageJ software. The summation of the entire ﬂuorescent
area on z-stack images from the top to the bottom of the CNV was used as an index
for the CNV volume.
Mice were perfused with 200 µl FITC-dextran (FD2000S, 5 mg/ml, molecular
weight 2,000,000, Sigma-Aldrich) before enucleation. After RPE-choroidal ﬂat-
mounting, the FITC-dextran perfused CNV was examined and analyzed as
previously described.
Immunoﬂuorescence of RPE-choroid ﬂat-mounts. Three days after laser
induction (peak of macrophage inﬁltration), RPE-choroid ﬂat-mounts were also
prepared for immunoﬂuorescence. A polyclonal rabbit anti-IBA1 antibody
(019–19741, 1:400, Wako, Neuss, Germany) was applied overnight at −4 °C. After
washing with 0.1% Triton X100/PBS, the ﬂat-mounts were incubated with Alex-
aFluo® 594 goat anti-rabbit IgG (A-11012, 1:200, ThermoFisherScientiﬁc, Saint
Aubin, France), the nuclei were counterstained with DAPI. Images of IBA1 positive
macrophage/microglia were observed and captured with a confocal microscope.
The IBA1 positive area was measured using the ImageJ software. The average
ﬂuorescent area per burn per eye was calculated.
Immunohistochemistry. Enucleated eyes were ﬁxed in 4% PFA for 2 h, dehydrated
and embedded in parafﬁn. Eight-µm-thick sections were deparafﬁnized in xylene,
hydrated in a graded alcohol series, and washed in PBS-Tween (PBST). After
antigen retrieval by heating in citrate buffer and inactivation of endogenous per-
oxidase by 3% H2O2, sections were incubated with 3% normal horse serum to
reduce the non-speciﬁc signal. Mouse monoclonal anti-MR 6G1 (1:100, kindly
provided by C. Gomez-Sanchez, Division of Endocrinology, University of Mis-
sissippi Medical Center, Jackson, MS) was applied overnight at 4 °C. After washing
in PBST, sections were incubated with the biotinylated horse anti-mouse IgG
BA2000 (1:250, Vector, AbCys, Paris, France) for 45 min at room temperature.
Ampliﬁcation of the signal was obtained with Tyramide Signal Ampliﬁcation
(TSA) kit (Perkin Elmer, Courtaboeuf, France) according to the manufacturer’s
instructions. Signal was revealed with 3,3’-diaminobenzidine tetrahydrochloride.
Negative controls were performed without a primary antibody.
Quantitative PCR. For QPCR in rats, eight laser impacts per eye were performed.
In all these experiments, n corresponds to the number of animals. Three days after
laser induction, the rat neuroretinas and RPE-choroid-sclera complexes were
carefully dissected from enucleated eyes, snap-frozen in liquid nitrogen and stored
at −80 °C until use. Total RNA was isolated from tissues using the RNeasyPlus
Mini Kit (Qiagen, Courtaboeuf, France) according to the manufacturer’s instruc-
tions. First-strand complementary DNA was synthesized from the total mRNA
using random primers (ThermoFisher Scientiﬁc) and SuperScript II reverse tran-
scriptase (ThermoFisher Scientiﬁc). Transcript levels of MR, MCP-1, IL6, IL1β,
TNFα, iNOS, VEGF-A, PlGF, HIF1α, ANGPTL4, TGFβ, and DCN were analyzed
by quantitative real-time PCR performed in 7500 Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) with either SYBR Green or TaqMan detection.
HPRT1 and 18S were used as housekeeping genes. Delta CT threshold calculation
was used for relative quantiﬁcation of results. Primers are as follows: MR, 5′-TAA
GTTTCCCCACGTGGTTC-3′ (forward), 5′-ATCCACGTCTCATGGCTTTC-3′
(reverse); MCP-1, 5′-CCTGCTGCTACTCATTCAC-3′ (forward), 5′-TCT CAC T
TG GTT CTG GTC C-3′ (reverse); VEGF-A, 5′-GCGGGCTGCTGCAATG-3′
(forward), 5′-TGCAACGCGAGTCTGTGTTT-3′ (reverse); PlGF, 5′-GTCCTTCT
GAGTCGCTGTAG-3′ (forward), 5′-TTCCTCCTTTCTGCCTTTGT-3′ (reverse);
HIF1α, 5′-GGTGGATATGTCTGGGTTGAG-3′ (forward), 5′-TTCAACTGGTTT
GAGGACAGA-3′ (reverse); ANGPTL4, 5′-TTCTCTACCTGGGACCAAGA-3′
(forward), 5′-CTGTAGTGGATAGTAGCGGC-3′ (reverse); TGFβ, 5′-CAG AAG
TTG GCA TGG TAG CC-3′ (forward), 5′-TGC TTC AGC TCC ACA GAG AA-3′
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(reverse); DCN, 5′-CTGCTATTCCTCAAGGTCTG-3′ (forward), 5′-AGGAACAT
TAGCCAGACTGC-3′ (reverse); HPRT1, 5′-GCGAAAGTGGAAAAGCCAAGT-
3′ (forward), 5′-GCCACATCAACAGGACTCTTGTAG-3′ (reverse); 18S, 5′-TGC
AATTATTCCCCATGAACG-3′ (forward), 5′-GCTTATGACCCGCACTTACTG
G-3′ (reverse). IL6,IL1β, TNFα, iNOS were assayed using Thermo Fisher TaqMan
(Assays IDs Rn01410330_m1,Rn00676333_g1, Rn01525859_g1,Rn00561646_m1)
with HPRT1 as housekeeping gene (Assay ID Rn01527840_m1).
IVT of recombinant DCN protein. We used recombinant mouse DCN protein
(R&D Systems) that shares 87% amino-acid sequence identity with rat DCN. IVT
of DCN was performed after laser induction at a ﬁnal concentration of 1 µg/ml or
10 µg/ml in the rat vitreous. FA was performed at day 14, and CNV quantiﬁcation
on choroidal ﬂat-mounts at day 16. Rat was chosen for this experiment as CNV is
more reproducibly induced in rats than in mice, the eye size is larger allowing
collection of more material and repeated injections are easier to perform in the
larger rat eye.
DCN silencing by siRNA in CNV model. Rat DCN stealth siRNAs (set of 3,
RSS307035, RSS307036, RSS307037) were purchased from ThermoFisher Scientiﬁc.
Stock solution was made by adding 1 ml H2O to 20 nMol DCN siRNA set. Before
IVT, for each rat, siRNA injection solution was prepared by mixing 2 µl siRNA
stock solution with 10 µl Mirus transfection reagent and vortexed. After laser
induction, 5 µl of siRNA solution was injected in each eye of a rat. Control rat eyes
were injected with scrambled siRNA (Stealth™ RNAi negative control, medium GC
duplex, ThermoFischer Scientiﬁc) prepared according to manufacturer’s instruc-
tion. Animals were sacriﬁced at day 2 after laser induction, and the RPE-choroid
complexes were retrieved for western blotting. To test the effect of DCN silencing
on CNV formation, DCN siRNA was injected intravitreously in rat eyes at day 0
and day 3 after laser induction. FA was then performed at day 14 to evaluate the
permeability of choroidal neovessels. CNV was stained using FITC-GSL I-Isolectin
B4 on RPE-choroid ﬂat-mounts and quantiﬁed using Image-J.
Western blotting. For protein analysis, we performed eight laser impacts per rat
eye. The experiment was repeated twice independently. The dissected RPE-
choroidal samples were processed using standard methods23 for western blotting.
Brieﬂy, equal amounts of protein (20 µg) were separated on Novex® 4–20% Tris-
Glycine gel (Thermo Fisher Scientiﬁc), transferred to nitrocellulose, and the blots
were incubated with rabbit anti-DCN (ab175404, 1:1000, Abcam, Cambridge, UK)
at 4 °C overnight. The membranes were then washed, incubated with HRP goat
anti-rabbit IgG antibody (PI-1000, 1:5000, vector) for 1 h at room temperature, and
developed using ECL Plus western blotting detection reagents (GE healthcare,
Orsay, France). Scans of blots were provided as Supplementary Fig. 10. The goat
anti-Actin (sc1616, 1:2500, Santa Cruz Biotechnology, Heidelberg, Germany) was
used as internal control.
Statistical analysis. In rat and mouse CNV models, in order to take into account
simultaneously the correlation between the two eyes of an animal and the corre-
lation for repeated measurements in the same eye (in case of repeated impacts), a
linear mixed model for repeated measures LMMRM (known to be robust to the
normality assumption) was used, including treatment (or mutation), side, time and
treatment х time as ﬁxed effects and animal as a random effect. No adjustment for
multiplicity was used at this level, knowing the exploratory purpose of the pre-
clinical data.
When pooling different experiments for comparison purposes, a speciﬁc model
(LMMRM) on control animals only was performed to check the comparability and
the lack of heterogeneity between experiments. As no signiﬁcant difference was
shown between controls (no experiment effect), the pooling was considered
interpretable.
Analyses were performed in SAS® 9.4 for Windows, SAS Institute Inc., Cary,
NC.
For data related to QPCR and western blot, comparison between two groups
was performed using Mann–Whitney U-test. Comparison between multiple groups
was analyzed using non-parametric Kruskal–Wallis followed by Dunns test
(GraphPad Prism 5 for Windows, GraphPad Software Inc., San Diego, CA, USA).
p-values of 0.05 or less were considered signiﬁcant.
RNA-sequencing and data analysis. Male 8-week-old Lewis rats were injected
intravitreously with aldosterone (20 nM ﬁnal concentration in the vitreous) and
sacriﬁced after 24 h. Control rats received vehicle injection. The whole retinas
(comprising neuroretina and RPE-choroid complex) were isolated for RNA-
sequencing. Total RNA was extracted using the RNeasyMini Kit (Qiagen) including
DNase I treatment. RNA integrity was checked on the Agilent 2100 Bioanalyzer. At
least three independent biological replicate samples were sequenced and used for
downstream analysis. RNA-sequencing was performed on Illumina HiSeq2000
platform. The average number of reads per sample was 27M. Reads from each
sample were processed as follows. First, reads were trimmed using an in-house Perl
script with a minimum phred quality of 20 per vase and a minimum read length of
30 bp. On average, 24% of reads per sample were discarded. The resulting reads
were later aligned to the Rattus Norvegicus genome assembly 3.4 (from Ensembl)
using Tophat version 2.0.10. At least 12 million reads were aligned to the genome
for each sample. We next quantiﬁed gene expression to obtain read count and
FPKM values. The non-adjusted read counts for each gene were used for statistical
calculation of global differential expression using DESeq2. Differentially expressed
genes were selected at an adjusted p-values of ≤ 0.05 and fold changes >1.5.
Differential expression between aldosterone- and vehicle-injected rats was also
analyzed using the GOlandscape, a threshold-free gene ontology tool (The
GOlanscape R-package and a detailed description of the tool are available at the
website https://github.com/andreaprunotto/GOlandscape). This software computes
a stepwise GO-analysis all over the range of DE signiﬁcance, assigning a p-value for
each GO term at each step. Then it selects the most signiﬁcant annotated categories
in the range, displaying them in combination with the most represented
annotated genes within these terms. The output is a heatmap, which enables the
analyst to identify quickly which gene is involved in which process (at the
maximum level of statistical signiﬁcance), independently on an arbitrary choice of
the DE genes list.
Code availability. The R code of GOlandscape used in this study and related
documentation are available at the websites https://github.com/andreaprunotto/
GOlandscape and https://zenodo.org/record/1474122.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this Article.
Data availability
All relevant data are available from the corresponding author upon reasonable
request. RNA-sequencing data are available from ArrayExpress database at EMBL-
EBI under accession number E-MTAB-7438. The images from ﬁgures are available
at ﬁgshare. A Reporting Summary for this Article is available as a Supplementary
Information ﬁle.
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